Ironwood Pharmaceuticals (IRWD) Common Equity (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Common Equity data on file, last reported at -$217.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 35.0% year-over-year to -$217.1 million; the trailing twelve-month figure through Mar 2026 stood at -$217.1 million (up 35.0% YoY), and the FY2025 full-year result was -$261.8 million, up 13.11% from the prior year.
• Common Equity climbed to -$217.1 million in Q1 2026, from -$261.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.4 billion in Q4 2023 to a low of -$346.8 million in Q2 2023.
• A 5-year average of $60.8 million and a median of -$264.2 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 369.89% in 2022 and plunged 165.08% in 2023, its largest moves.
• Tracing IRWD's Common Equity over 5 years: stood at $652.4 million in 2022, then soared by 107.73% to $1.4 billion in 2023, then slumped by 122.24% to -$301.3 million in 2024, then advanced by 13.11% to -$261.8 million in 2025, then advanced by 17.07% to -$217.1 million in 2026.
• Business Quant data shows IRWD's Common Equity at -$217.1 million in Q1 2026, -$261.8 million in Q4 2025, and -$264.2 million in Q3 2025.